Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.

ABSTRACT:

Background

The perception that older cancer patients may be at higher risk than younger patients of toxic effects from cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how older patients respond to targeted therapy.

Methods

This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age >or=70 years, n = 115) and younger patients (age <70 years, n = 787) who received treatment for advanced renal cell carcinoma. Patient demographics and progression-free survival were recorded. Best tumor respo

SUBMITTER: Eisen T 

PROVIDER: S-EPMC2567417 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature